Desvenlafaxine
NDC Package 53002-1801-3

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Desvenlafaxine is extended-release tablets are indicated for the treatment of adults with major depressive disorder (MDD) [see Clinical Studies (14)]. Marketed by Rpk Pharmaceuticals, Inc., this product is identified by NDC 53002-1801 and is authorized under FDA application ANDA204065.

Identification & Billing

NDC Package Code
53002-1801-3
Package Description
30 TABLET, EXTENDED RELEASE in 1 BOTTLE
Product Code
53002-1801
11-Digit Billing Format
53002180103
RxNorm Crosswalk
  • RxCUI: 1874559 - desvenlafaxine succinate 50 MG 24HR Extended Release Oral Tablet
  • RxCUI: 1874559 - 24 HR desvenlafaxine succinate 50 MG Extended Release Oral Tablet
  • RxCUI: 1874559 - desvenlafaxine 50 MG (as desvenlafaxine succinate 76 MG) 24HR Extended Release Oral Tablet

Clinical Specifications

Proprietary Name
Desvenlafaxine
Dosage Form
-
Usage Information
Desvenlafaxine extended-release tablets are indicated for the treatment of adults with major depressive disorder (MDD) [see Clinical Studies (14)].

Regulatory & Marketing

Labeler Name
Rpk Pharmaceuticals, Inc.
FDA Application #
ANDA204065
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
03-01-2017
Listing Expiration
12-31-2024
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 53002-1801-3 identifies a specific commercial package of 30 tablet, extended release in 1 bottle of Desvenlafaxine, labeled by Rpk Pharmaceuticals, Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Rpk Pharmaceuticals, Inc. on March 01, 2017. The current certification is valid through December 31, 2024.

How is this Rpk Pharmaceuticals, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 53002180103. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
53002-1801-3
11-Digit CMS (5-4-2)
53002-1801-03

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.